Compare Invesco Preferred ETF (PGX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Smith & Nephew plc — how do they compare? Invesco Preferred ETF trades at $10.04 (market cap $3.64B), while Smith & Nephew plc trades at $26.9 (market cap $11.31B). The key difference: Smith & Nephew plc is far larger — about 3.1× Invesco Preferred ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 94 Days and Smith & Nephew plc for 120 Days on average.
| PGX | SNN | |
|---|---|---|
Market Cap | $3.64B | $11.31B |
Volume | 6,969,114 | 1,050,005 |
52-Week High | $11.61 | $37.17 |
52-Week Low | $9.97 | $26.42 |
Typical Hold Time | 94 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $14.35B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $9.97, down 0.89% with a bearish technical signal from moving averages despite oversold RSI readings. The stock shows identical support and resistance at $10, indicating consolidation. Recent dividend payments of $0.06 were declared for July and September 2026, providing income appeal. Financial ratios including P/E, P/S, and ROE are unavailable in current data, limiting fundamental visibility.
The outlook remains cautious due to bearish technical momentum and lack of current financial metrics. Income investors may find dividend payments attractive, but absence of earnings data and weak price action suggest near-term pressure. Key risks include undefined profitability and competitive challenges in the preferred ETF space highlighted by recent media coverage.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
